Isis Pharmaceuticals Inc.

Dr. Crooke is Founder, Chairman and Chief Executive Officer of Isis Pharmaceuticals. Since Dr. Crooke and his colleagues founded Isis in 1989, the Company has grown rapidly, completing its initial public offering in May 1991, and has reported broad progress in antisense technology and its rapid conversion to therapeutic product opportunities. Isis was the first company to commercialize an antisense drug and has achieved a number of important corporate collaborative relationships. Dr. Crooke is currently a member of the Northern Arizona University Arts and Sciences Advisory Council, Flagstaff, Arizona, and San Diego State University BioScience Center Scientific Advisory Board. He is a member of the Current Drugs Advisory Board, the Editorial Advisory Board of Journal of Drug Targeting and Antisense Research and Development, the Editorial Board of Gene Therapy and Molecular Biology. He is also Editor-in-Chief of Current Opinion in Anticancer Drugs and Section Editor for Biologicals and Immunologicals for Expert Opinion on Investigational Drugs. Prior to founding Isis, Dr. Crooke was President of Research and Development for SmithKline Beckman Corporation (SKB). He also coordinated the research and development activities of SKB including its instruments, diagnostics, animal health and clinical laboratory businesses. Prior to joining SKB, Dr. Crooke helped establish the anticancer drug discovery and development program at Bristol Myers, which succeeded in bringing to market a significant number of drugs. During his career, Dr. Crooke has supervised the development of 19 drugs currently on the market and others in development. In addition to his involvement in the pharmaceutical industry, Dr. Crooke also maintains active academic positions. He is an adjunct professor at San Diego State University, and has won a number of teaching awards. He has authored over 435 publications and has edited 19 books. Dr. Crooke is active in molecular and cellular biology and pharmacology of antisense oligonucleotides. Dr. Crooke received his M.D. and Ph.D. from Baylor College of Medicine, Houston, Texas and his B.S. in Pharmacy from Butler University, Indianapolis, Indiana.

Dr. Bennett is Senior Vice President of Research at Isis Pharmaceuticals. He is responsible for preclinical antisense drug discovery research. Dr. Bennett is one of the founding members of the company. He has been involved in the development of antisense oligonucleotides as therapeutic agents, including research on the application of oligonucleotides for inflammatory and cancer targets, oligonucleotide delivery and pharmacokinetics. He also runs the company's antisense mechanism program which is focused on the development of RNase H, RNAi, micro-RNA and splicing. Dr. Bennett has published more than 90 papers in the field of antisense research and development and has more than 100 issued U.S. patents. Prior to joining Isis, Dr. Bennett was Associate Senior Investigator in the Department of Molecular Pharmacology at SmithKline and French Laboratories, GlaxoSmithKline (currently, GlaxoSmithKline). Dr. Bennett received his B.S. degree in Pharmacy from the University of New Mexico, Albuquerque, New Mexico and his Ph.D. in Pharmacology from Baylor College of Medicine, Houston, Texas. Dr. Bennett performed his postdoctoral research in the Department of Molecular Pharmacology at SmithKline and French Laboratories, where he studied the signal transduction pathway of leukotrienes.

Mr. Treble is Vice President of Isis and President of Ibis Biosciences, Inc., a wholly owned subsidiary of Isis. Mr. Treble is responsible for spearheading the strategic direction and commercialization of the Company's Ibis T5000 Biosensor System. Prior to joining Isis in December 2004, Mr. Treble was a founder of Tienta Sciences, Inc. and SonoPlot, Inc., venture start-up companies based upon technology licensing applications from Purdue and Wisconsin Universities. Prior to that, Mr. Treble was President and CEO of NimbleGen Systems, Inc., a genomics-based company that produces high-density custom DNA arrays for academic, bio-pharm and ag-bio applications. Mr. Treble was also the Executive Vice President, Chief Operating Officer and Director of Third Wave Technologies, Inc., a leader in the genomics diagnostic field. Additionally, he served as Director of Marketing and Field Services for Roche Diagnostics and as Marketing Manager for Abbott Diagnostics. Mr. Treble is on the Board of Gentra Systems, Inc., a private, venture backed DNA/RNA sample preparation platform company located in Minneapolis, MN. He is also on the Board of Axela Biosensors, Inc., a protein analysis start-up company located in Toronto, Canada. Mr. Treble received his Master of Business Administration degree from the University of Buffalo and Bachelor of Science from Canisius College, Buffalo, NY.

Mr. Wender has served as a Director of Isis since January 1994. Mr. Wender began with Goldman, Sachs & Co. in 1971 and became a General Partner of that firm in 1982, where he headed the Financial Institutions Group for over a decade. Mr. Wender worked at GSC Group from 2005 through 2007 where he was a Senior Managing Director, member of the Management Committee, and Chairman of the Finance Committee. Since January 2008, he has been a Senior Consultant to Goldman Sachs & Co. He sits on the Board of Affinity Financial, a privately-held Internet financial institution, and Vintrust, a privately-held wine management company. He is also an Independent Trustee of the Schwab Family of Funds.

Joseph Klein, III , age 46, has served as a Director of Isis since December 2005. Mr. Klein is currently Managing Director of Gauss Capital Advisors, LLC, a financial consulting and investment advisory firm focused on biopharmaceuticals, which he founded in March 1998. In addition to his investment advisory and financial consulting activities, Mr. Klein currently serves as a Venture Partner of Red Abbey Venture Partners, LP, a life sciences private equity fund. From September 2001 to September 2002, Mr. Klein was a Venture Partner of MPM Capital, a healthcare venture capital firm. From June 1999 to September 2000 when it merged with WebMD Corporation, Mr. Klein served as Vice President, Strategy for Medical Manager Corporation, a leading developer of physician office management information systems. Mr. Klein serves on the board of directors of four publicly held biotechnology companies: BioMarin Pharmaceutical Inc. since June 2005; NPS Pharmaceuticals, Inc. since 1998, but does not intend to stand for reelection to NPS board at its annual meeting in May 2007; OSI Pharmaceuticals, Inc. since July 2006; and Savient Pharmaceuticals, Inc. since May 2006.

Patrick F. Latterell has served on our Board since July 2002. Mr. Latterell is the founder of Latterell Venture Partners, a venture capital firm, and has served as the Managing Member of its general partner entities since 2001. Prior to forming Latterell Venture Partners, Mr. Latterell was a General Partner at Venrock Associates, which he joined in 1989. Mr. Latterell served as Chairman of the National Venture Capital Association Medical Industry Group in 2003 and 2004, and also serves on the boards of several privately-held medical device companies. Mr. Latterell holds an S.B. in Biological Sciences and an S.B. in Economics from the Massachusetts Institute of Technology, and an M.B.A. from Stanford University.

Frederick T. Muto has served as a Director of Isis since March 2001. Mr. Muto joined the law firm of Cooley Godward LLP, outside counsel to Isis, in 1980 and became a partner in 1986. He is a founding partner of Cooley Godward's San Diego office and serves as the partner in charge of that office. Mr. Muto also serves on that firm's management committee.

Mr. Skaletsky has been a director of Alkermes since June 2004. He is currently Chairman, CEO and President of Trine Pharmaceuticals, Inc. Previously, Mr. Skaletsky was President and CEO of GelTex Pharmaceuticals, Inc. which was acquired by Genzyme in December 2000. Mr. Skaletsky held the position of Chairman and CEO of Enzytech, Inc., from 1988 to 1993, and he was President and Chief Operating Officer of Biogen, Inc., from 1981 to 1988. Mr. Skaletsky was among the founders of the Industrial Biotechnology Association, a predecessor to the Biotechnology Industry Organization (BIO), and is a former chairman of BIO. He serves on the Board of Directors of ImmunoGen, Inc., Dormantis, Inc., Advanced Magnetics, Inc, Targacept, Inc., and Icoria, Inc. In addition, Mr. Skaletsky is a member of the Board of Trustees of Bentley College.

Dr. DiMarchi is the Linda & Jack Gill Chair in Biomolecular Sciences and Professor of Chemistry at Indiana University. He is a retired Group Vice President at Eli Lilly & Company where for more than two decades he provided leadership in biotechnology, endocrine research and product development. He currently serves as a co-founder and Board Chairman of Ambrx, Inc. He previously served as a board member to the biotechnology trade group BIO and the American Peptide Society, as well as such companies as Millennium Biotherapeutics and Inproteo. He currently serves as Board member to Isis Pharma. and Alba. He is a scientific advisor to Epitome Biosciences, Kai Pharmaceuticals, Semafore Biotechnologies, 5AM Ventures, and Twilight Ventures. Professor DiMarchi is recognized for discovery and development of rDNA-derived Humalog (LisPro-human insulin). As scientist and administrator Dr. DiMarchi participated in the commercial development of Humulin , Humatrope , Xigris , and Forteo while at Lilly. He recently received the 2005 AAPS Research Achievement Award in Biotechnology and the 2006 ACS Earle B. Barnes Award for Leadership in Chemical Research Management.